Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock

HAYWARD, Calif., March 23, 2015 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 5,555,556 shares of its common stock, offered at a price of $4.50 per share.  In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock to cover over-allotments, if any.  The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were approximately $25,000,000 million.  Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.

Piper Jaffray & Co. has acted as sole underwriter in the offering. The Trout Group, LLC has acted as advisor to the Company.

The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These  forward-looking statements include statements about Anthera's expectations with respect to its public offering, including statements about its intended use of proceeds from the offering.  Such statements are based on Anthera's  expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's  Annual Report on Form 10-K for the year ended December 31, 2014.  Anthera  disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., [email protected] or 510.856.5598.

SOURCE Anthera Pharmaceuticals, Inc.

Related Links

http://www.anthera.com